Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00328741 | Colorectum | CRC | positive regulation of stress-activated MAPK cascade | 24/2078 | 126/18723 | 5.68e-03 | 4.26e-02 | 24 |
GO:00107661 | Colorectum | CRC | negative regulation of sodium ion transport | 7/2078 | 21/18723 | 5.85e-03 | 4.32e-02 | 7 |
GO:00423265 | Colorectum | CRC | negative regulation of phosphorylation | 59/2078 | 385/18723 | 6.45e-03 | 4.67e-02 | 59 |
GO:1901016 | Colorectum | CRC | regulation of potassium ion transmembrane transporter activity | 15/2078 | 68/18723 | 6.77e-03 | 4.77e-02 | 15 |
GO:00329411 | Colorectum | CRC | secretion by tissue | 10/2078 | 38/18723 | 7.08e-03 | 4.92e-02 | 10 |
GO:003164716 | Endometrium | AEH | regulation of protein stability | 77/2100 | 298/18723 | 1.13e-12 | 2.26e-10 | 77 |
GO:200123316 | Endometrium | AEH | regulation of apoptotic signaling pathway | 86/2100 | 356/18723 | 2.97e-12 | 4.95e-10 | 86 |
GO:005082116 | Endometrium | AEH | protein stabilization | 55/2100 | 191/18723 | 2.19e-11 | 3.20e-09 | 55 |
GO:00614589 | Endometrium | AEH | reproductive system development | 88/2100 | 427/18723 | 9.50e-09 | 6.41e-07 | 88 |
GO:00486089 | Endometrium | AEH | reproductive structure development | 87/2100 | 424/18723 | 1.43e-08 | 9.12e-07 | 87 |
GO:005109816 | Endometrium | AEH | regulation of binding | 77/2100 | 363/18723 | 2.21e-08 | 1.31e-06 | 77 |
GO:00301118 | Endometrium | AEH | regulation of Wnt signaling pathway | 71/2100 | 328/18723 | 3.31e-08 | 1.87e-06 | 71 |
GO:20012358 | Endometrium | AEH | positive regulation of apoptotic signaling pathway | 36/2100 | 126/18723 | 7.56e-08 | 3.92e-06 | 36 |
GO:006219716 | Endometrium | AEH | cellular response to chemical stress | 71/2100 | 337/18723 | 1.03e-07 | 5.05e-06 | 71 |
GO:00018909 | Endometrium | AEH | placenta development | 39/2100 | 144/18723 | 1.07e-07 | 5.20e-06 | 39 |
GO:00160558 | Endometrium | AEH | Wnt signaling pathway | 85/2100 | 444/18723 | 4.99e-07 | 1.97e-05 | 85 |
GO:01987388 | Endometrium | AEH | cell-cell signaling by wnt | 85/2100 | 446/18723 | 6.07e-07 | 2.29e-05 | 85 |
GO:00017019 | Endometrium | AEH | in utero embryonic development | 73/2100 | 367/18723 | 7.18e-07 | 2.63e-05 | 73 |
GO:009719116 | Endometrium | AEH | extrinsic apoptotic signaling pathway | 49/2100 | 219/18723 | 1.58e-06 | 4.94e-05 | 49 |
GO:00608288 | Endometrium | AEH | regulation of canonical Wnt signaling pathway | 54/2100 | 253/18723 | 2.22e-06 | 6.56e-05 | 54 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STK3 | SNV | Missense_Mutation | | c.533N>T | p.Gly178Val | p.G178V | Q13188 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STK3 | SNV | Missense_Mutation | rs545643657 | c.1306N>A | p.Glu436Lys | p.E436K | Q13188 | protein_coding | tolerated(0.62) | benign(0.007) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STK3 | SNV | Missense_Mutation | novel | c.1419N>T | p.Leu473Phe | p.L473F | Q13188 | protein_coding | tolerated(0.63) | benign(0.013) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
STK3 | insertion | Nonsense_Mutation | novel | c.775_776insAGAAATCAG | p.Phe259delinsTer | p.F259delins* | Q13188 | protein_coding | | | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
STK3 | insertion | Frame_Shift_Ins | novel | c.1417_1418insCC | p.Leu473SerfsTer2 | p.L473Sfs*2 | Q13188 | protein_coding | | | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
STK3 | insertion | Frame_Shift_Ins | novel | c.719_720insCCTCAGACCAAAGAAG | p.Glu241LeufsTer9 | p.E241Lfs*9 | Q13188 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STK3 | SNV | Missense_Mutation | | c.244N>A | p.Ala82Thr | p.A82T | Q13188 | protein_coding | deleterious(0.02) | probably_damaging(0.981) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
STK3 | SNV | Missense_Mutation | novel | c.541N>T | p.Leu181Phe | p.L181F | Q13188 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-EA-A3Y4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
STK3 | SNV | Missense_Mutation | | c.721N>C | p.Glu241Gln | p.E241Q | Q13188 | protein_coding | deleterious(0.04) | probably_damaging(0.987) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
STK3 | SNV | Missense_Mutation | | c.425N>A | p.Arg142Gln | p.R142Q | Q13188 | protein_coding | tolerated(0.06) | possibly_damaging(0.723) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6788 | STK3 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | SOTRASTAURIN | SOTRASTAURIN | |
6788 | STK3 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | ALSTERPAULLONE | ALSTERPAULLONE | |
6788 | STK3 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | SP-600125 | SP-600125 | 23634759 |
6788 | STK3 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | 249565869 | CEP-11981 | |
6788 | STK3 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | BAY-613606 | CHEMBL541400 | |
6788 | STK3 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | TAE-684 | TAE-684 | |
6788 | STK3 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | LAUROGUADINE | LAUROGUADINE | |
6788 | STK3 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | PF-562271 | PF-00562271 | |
6788 | STK3 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | GW441756X | GW441756X | |
6788 | STK3 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | ILORASERTIB | ILORASERTIB | |